Compound class:
Synthetic organic
Comment: eAmSPC 2593 is the lead from a new class of N-ethylene linked aminomethyl spectinomycins (eAmSPCs), discovered following modification of spectinomycin, and with promising antimycobacterial activity [2]. The structure is claimed in patent WO2015048692A1 filed by St. Jude Children's Research Hospital [1].
|
|
Bioactivity Comments |
eAmSPC 2593 demonstrates activity in vitro against M. tuberculosis H37Rv (MIC of 3.13 μg/ml), M. abscessus (MIC of 4 μg/ml), other nontuberculous mycobacteria (NTM, MIC range 0.2-12.5 μg/ml), and Gram-positive bacteria but was ineffective against most Gram-negative bacteria tested with the exception of Escherichia coli [2]. An IC50 value of 1.01 μM is reported for translation inhibitory activity of eAmSPC 2593 against Mycobacterium smegmatis ribosomes in cell-free translation assays [2]. |